NDA 213498 · Vanda Pharms INC
Ponvory
Ponesimod · Oral · Sphingosine 1-phosphate Receptor Modulator
NovelCDER novel approval, Mar 18, 2021: To treat relapsing forms of multiple sclerosis
Last checked: Nov 20, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Mar 18, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
5 Phase 3, 2 recruiting
FAERS reports
438
166 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2026.
PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Mechanism: Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1. Ponesimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which ponesimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- PONVORY · PONESIMOD 20MG · TABLET, ORAL · Prescription
- PONVORY · PONESIMOD 20MG · TABLET, ORAL · Prescription
- PONVORY · PONESIMOD 2MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ponesimod" as an intervention, any sponsor and status, largest first.
- Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT02425644 · 1,133 participants · Start Jun 4, 2015 · Primary completion May 16, 2019
Drug: ponesimod; teriflunomide · For: Multiple Sclerosis
Sites: Carlsbad, California; Pomona, California; Denver, Colorado · 162 sites in all
- Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT03232073 · 877 participants · Start Jul 5, 2017 · Primary completion Jan 16, 2024
Drug: Ponesimod · For: Multiple Sclerosis
Sites: Carlsbad, California; Pomona, California; Denver, Colorado · 148 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple SclerosisPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01006265 · 464 participants · Start Oct 1, 2009 · Primary completion Jun 1, 2011
Drug: ACT-128800 Dose 1; Placebo and 2 more · For: Multiple Sclerosis
Sites: Scottsdale, Arizona; Tucson, Arizona; Sacramento, California · 115 sites in all
- Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01093326 · 353 participants · Start May 12, 2010 · Primary completion Sep 6, 2023
Drug: Ponesimod 10 mg; Ponesimod 20 mg and 1 more · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Palo Alto, California · 71 sites in all
- ACT-128800 in Patients With Moderate to Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01208090 · 326 participants · Start Oct 31, 2010 · Primary completion Oct 31, 2012
Drug: ACT-128800; Placebo · For: Psoriasis
Sites: Feldkirch, Austria; Graz, Austria; Sankt Pölten, Austria · 67 sites in all
- Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisPivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT07362017 · 300 participants (planned) · Start Feb 17, 2026 · Primary completion Aug 2028
Drug: Ponesimod · For: Moderate-to-severe Chronic Plaque Psoriasis
Sites: Glendale, Arizona; Fremont, California; Miami, Florida · 10 sites in all
- Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
Vanda PharmaceuticalsIndustry
NCT07686081 · 150 participants (planned) · Start Sep 2026 · Primary completion Apr 2029
Drug: Ponesimod; Placebo · For: Ulcerative Colitis (UC)
Sites: Chula Vista, California; Nashville, Tennessee
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue76
- fatigue35
- dizziness25
- dyspnoea24
- headache22
- product use issue17
- nausea14
- covid-1913
- drug ineffective13
- pain12
- hypoaesthesia11
- somnolence11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 34 |
| 2022 | 135 |
| 2023 | 78 |
| 2024 | 29 |
| 2025 | 42 |
| 2026 | 119 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ponvory (Ponesimod)
2024 spending
$6.4M
Beneficiaries
79
528 claims
Per beneficiary
$80,600
$313.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $568,668 |
| 2022 | $4,610,821 |
| 2023 | $8,307,094 |
| 2024 | $6,367,371 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA, Drudge C, Walsh S, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L, Fox RJ, Burcklen M, et al. · JAMA Neurol 2021 · Comparative Study, Randomized Controlled Trial
- Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment - a systematic review and network meta-analysis.
Köhler M, Paul F, Janke K, et al. · BMC Neurol 2025 · Comparative Study, Network Meta-Analysis
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis.
Ridley B, Minozzi S, Gonzalez-Lorenzo M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Effects of Sphingosine 1-phosphate Modulators on Central Remyelination: A Systematic Review of Animal Models.
Vu H, George N, Xiao J · Cell Mol Neurobiol 2026 · Systematic Review
Sponsor: Vanda Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.